BTK and Bruton-type agammaglobulinemia: A proteomic screening approach using tandem mass spectrometry was additionally described to quantify signature peptides for BTK, WASP, and T-cell marker CD3ε to screen for XLA, Wiskott–Aldrich Syndrome (WAS), and SCID, respectively [57].